Ibogaine and methadone cannot be combined directly. Methadone prolongs the QT interval on an EKG by blocking hERG potassium channels in the heart—ibogaine blocks the same channels as a secondary pharmacological effect. Administering ibogaine to someone who has not cleared methadone significantly raises the risk of a life-threatening cardiac arrhythmia during the 12–24 hour ceremony. This is why the protocol is not simply “stop methadone before ceremony.” It is a physician-supervised transition to a shorter-acting opioid, followed by a clearance period confirmed by cardiac assessment.
People on methadone maintenance therapy can pursue ibogaine ceremony. The path is longer than for someone on a short-acting opioid—typically months, not weeks—and it requires medical coordination that not everyone has immediate access to. Whether the process is feasible for any specific person is answered through the intake process, not assumed in either direction.
Key facts
- Methadone and ibogaine both block hERG potassium channels—combining them without a transition protocol creates compounded cardiac risk
- Methadone half-life: 24–36 hours in most patients, up to 59 hours in some individuals; it accumulates in fatty tissue and clears slowly
- Transition protocol typically takes several months, not days or weeks
- Ibogaine ceremony at Transcend: $2,000–$5,000 CAD, on-site physician and continuous cardiac ECG monitoring included throughout
- Pre-ceremony EKG required regardless of time since last methadone dose
- Every application receives a personal response within 2–3 business days
What makes methadone different from other opioids
Most people who ask about ibogaine and methadone already understand that ibogaine requires clearing opioids before ceremony. What is less widely understood is why methadone presents a categorically different problem from other opioids—and why the approach that works for someone on heroin or oxycodone does not work for someone on methadone maintenance.
The first factor is half-life. Heroin clears in hours. Oxycodone and hydrocodone clear in roughly a day. Methadone has a half-life of 24–36 hours in most patients—and in some individuals that half-life can reach 59 hours. Someone on daily maintenance doses has methadone accumulating in fatty tissue and releasing slowly over time. A week of abstinence from heroin clears the drug. A week of abstinence from methadone does not.
The second factor is cardiac pharmacology. Methadone is one of a relatively small number of medications that blocks hERG potassium channels in the heart—channels responsible for cardiac repolarization. Blocking these channels prolongs the QT interval on an EKG. A prolonged QT interval is not itself a crisis; it is a marker that the electrical system of the heart is more vulnerable than usual to a potentially fatal arrhythmia called torsades de pointes. Ibogaine independently blocks the same hERG channels. The cardiac mechanism of ibogaine is the reason cardiac screening is required before every ceremony—and it is exactly why methadone requires more than timing a cessation.
How the cardiac risk actually works
Ibogaine's effect on the QT interval peaks during the active experience. The 12–24 hour ceremony is the window of maximum cardiac exposure. A pre-ceremony EKG confirms that the baseline QT is within acceptable range before administration. An on-site physician monitors ECG throughout the ceremony for the same reason.
For someone with QT prolongation from methadone, two problems compound. First, the baseline QT is already elevated—ibogaine adds to an elevated baseline, not a normal one. Second, methadone clears slowly enough that an EKG taken one week after stopping may not reflect how much methadone remains in the system. Fatty tissue continues releasing methadone after dosing stops. The EKG is a snapshot; the pharmacological load can lag behind it.
This is why the protocol is not “stop methadone, wait long enough, then proceed.” There is no universally safe interval that applies to methadone cessation. The protocol requires actively transitioning to a different substance—one that clears predictably—so that the cardiac baseline entering ceremony reflects accurate information rather than an incomplete picture.
Any ibogaine provider who accepts someone on methadone without a documented, physician-supervised transition is not operating safely. Published ibogaine fatalities consistently involve either unidentified cardiac conditions at baseline or the absence of physician monitoring during ceremony. Methadone is among the most common contributors to the first category.
The transition protocol: three phases
There is no single universally standardised methadone-to-ibogaine protocol. This is not well-funded, RCT-driven clinical territory. What practitioners and addiction medicine physicians have developed involves a consistent three-phase structure, even when specific timelines and substances vary by individual.
Phase one: supervised dose reduction.The process begins with a gradual, medically supervised reduction in methadone dose. Abrupt cessation is not appropriate—it is unsafe for most people on maintenance therapy and would destabilise preparation for ceremony. The reduction timeline depends on the starting dose and the person's stability, but it typically takes weeks to months. This phase requires the prescribing physician's direct involvement. It cannot be managed unilaterally.
Phase two: transition to a shorter-acting opioid.Once at a sufficiently low methadone dose, the person transitions to a short-acting opioid under medical supervision. Morphine is the most common choice in established protocols. The objective is to replace the long-acting drug—which clears slowly and unpredictably—with one that has a predictable, shorter clearance window. This phase maintains opioid function during the transition while allowing methadone to dissipate from fatty tissue.
Phase three: clearance and confirmation.After the final dose of the shorter-acting opioid, a clearance period precedes ibogaine ceremony. A short-acting opioid produces a standard withdrawal window—difficult, but not the extended and unpredictable clearance problem that methadone presents. When the short-acting opioid has cleared, a pre-ceremony EKG and full medical assessment confirms that the cardiac baseline meets the threshold for safe administration.
The full three-phase process from daily methadone maintenance to ibogaine ceremony readiness typically takes a minimum of several months. For someone on high-dose maintenance therapy, it may take longer. The timeline is determined by clinical reality, not by how ready the person feels or how urgently they want to proceed.
How long this process takes—and why that matters
The people asking most urgently about ibogaine and methadone are usually those who have been struggling the longest. Years of trying other approaches. Maintenance therapy that holds the situation stable without resolving it. The search for something that produces genuine change rather than ongoing management.
This is the pattern the medicine sees consistently: the people who come to ibogaine ceremony with the strongest responses are often those who spent years trying everything else first. SSRIs that blunted without resolving. Abstinence programmes that held for months, then did not. By the time they arrive, they are not naive about the difficulty. They have evidence that the easier paths did not hold. That scepticism—earned the hard way—tends to produce people who are genuinely ready to encounter what ibogaine shows them.
The months-long transition timeline is not an obstacle to ceremony. It is preparation. That period can be used to understand what the medicine produces and does not produce, what the integration period after ceremony requires, and what needs to be different in the environment and relationships the person returns to. People who arrive having done that work use the neuroplasticity window that follows ceremony more effectively than people who arrive without that preparation.
The relevant question is not whether the process takes longer than expected—it does. The relevant question is whether beginning that process now produces an outcome that is not otherwise accessible. For most people on maintenance therapy who have exhausted other approaches, ibogaine's neurological reset represents a genuine mechanism for change that maintenance therapy alone does not provide.
A note on buprenorphine as a bridge
Some practitioners and patients have explored buprenorphine as an intermediate step between methadone and ibogaine. The reasoning is that buprenorphine's half-life, while long, is more predictable than methadone's, and transitioning to it might address the methadone clearance problem before the final ibogaine preparation.
In practice, buprenorphine creates its own complications. Its high binding affinity at mu-opioid receptors means it can precipitate acute withdrawal when combined with opioid-active substances. Buprenorphine also requires its own clearance period before ibogaine can be safely administered, and its interactions with ibogaine are less well-characterised in the existing literature than the standard methadone-to-short-acting-opioid protocol. Using buprenorphine as a bridge does not simplify the process. Whether it is the right intermediate step for a specific person requires direct discussion with a physician experienced in ibogaine preparation—not inferred from general pharmacology.
The 2023 Stanford study in Nature Medicine documented outcomes in 30 special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression at one month post-ceremony: 88% reduction in PTSD symptoms, 87% in depression, 81% in anxiety. That evidence base was built with people whose opioid history, where present, was carefully managed before ibogaine. The preparation is not separate from the outcome.
Who Is Not Right for This
People who cannot complete a physician-supervised methadone transition protocol are not appropriate candidates for ibogaine ceremony, regardless of how ready they feel or how long they have been struggling. The cardiac risk of proceeding without adequate clearance is not a calculated risk tolerance. It is an absolute disqualifier.
People in active opioid use disorder crisis are not appropriate candidates. The months-long preparation process requires a baseline level of stability that someone in acute crisis does not have. Ibogaine ceremony amplifies what is present. Entering it in a state of acute instability does not produce stability.
People with QT prolongation confirmed on EKG even after completing the transition protocol are not appropriate candidates. Some people carry genetic variants that predispose them to QT prolongation regardless of medication status. The pre-ceremony EKG identifies this. A prolonged QT is a disqualifier even when the methadone transition has been completed correctly and on schedule.
People with cardiac history beyond QT prolongation—recent myocardial infarction, severe arrhythmia, or significant structural heart disease—are not appropriate candidates regardless of medication status.
People with severe liver or kidney disease are not appropriate candidates. Ibogaine is metabolized primarily by the liver. Pre-ceremony medical screening includes a blood panel that assesses hepatic and renal function specifically. These screening requirements apply whether or not methadone is in the picture.
People whose primary goal is to stop taking methadone—rather than addressing a specific presenting condition that maintenance therapy has not resolved—are not appropriate candidates. Ibogaine produces a neurological reset that creates a window for change. “Not being on medication” is not, by itself, a sufficient answer to the question of what change is being sought and worked toward.
Is This Right for You?
If you are on methadone and considering ibogaine, the first question is not whether ibogaine is appropriate in principle. The first question is whether the transition protocol is medically feasible given your cardiac history, your current dose, and whether your prescribing physician can be involved in the process.
The ceremony page covers what ibogaine ceremony at Transcend involves: the medical infrastructure, the 12–24 hour active experience, what the on-site physician monitors throughout, and the 2–3 day supervised recovery period on site.
The FAQ covers absolute contraindications in detail, including why the methadone requirement cannot be resolved by timing alone.
The integration page describes what the post-ceremony period requires—preparation worth beginning well before ceremony, not after.
Active ibogaine clinical trials—including trials examining ibogaine for opioid use disorder—are listed at ClinicalTrials.gov and are relevant for anyone on maintenance therapy tracking the developing evidence base.
If you have reviewed these and believe the transition protocol is feasible for your situation, the application is where the intake process begins. Every application receives a personal response within 2–3 business days. That response will include direct questions about your medication history and cardiac status—this is where the feasibility of your specific situation gets assessed honestly.